The Centers for Disease Control and Prevention opened three consultations on November 16, 2026, seeking input on proposed development goals for a human West Nile virus vaccine, a rapid diagnostic test and preventive monoclonal antibodies. Written comments are due January 15, 2027, giving researchers, clinical laboratories and product developers a shared deadline to help shape the profiles.
Three proposed profiles, three separate dockets
CDC’s Federal Register notices seek feedback on target product profiles: documents that set out the characteristics a future product should have to address an unmet clinical need. The agency describes these profiles as tools for establishing priorities and expectations during development, including minimally acceptable and preferred performance characteristics.
The vaccine notice covers a human vaccine. The antibody notice addresses preventive products for people at higher risk of severe West Nile virus disease. The diagnostic notice focuses on an assay for hospitals and clinical laboratories. Each proposed profile is identified as supplemental information in its corresponding Regulations.gov docket.
| Product profile | Docket | Questions CDC highlights | Written-comment deadline |
|---|---|---|---|
| Human West Nile virus vaccine | CDC-2026-1686 | Prevention value, likely commercial market and recommended profile changes | January 15, 2027 |
| Preventive monoclonal antibodies | CDC-2026-1685 | Prevention value, likely commercial market and recommended profile changes | January 15, 2027 |
| Rapid diagnostic test | CDC-2026-1684 | Clinical usefulness, evaluating potential interventions, market prospects and profile changes | January 15, 2027 |
These are requests for information on proposed research and development goals. They do not approve products or establish a vaccination programme. For research offices tracking regulatory affairs, the immediate action is an opportunity to submit evidence and recommendations during the comment period.
The diagnostic consultation includes a research question
In the rapid-test notice, CDC says its aim is to improve the likelihood of developing a commercially available assay for rapid diagnosis of West Nile virus infection. Its four questions connect the proposed test to both clinical care and research.
The agency asks whether a rapid assay would improve clinical care and whether it would help evaluate potential preventive or therapeutic interventions. It also asks whether a commercial market likely exists and what changes or considerations should be incorporated before the profile is finalised. For laboratories working on rapid diagnostic tests, this creates a defined channel for contributing evidence about the proposed product’s usefulness and development goals.
The vaccine and antibody notices each pose three questions: the product’s importance for prevention, whether a commercial market likely exists, and recommended changes to the draft profile. Market viability is therefore an explicit topic for comment across all three consultations, alongside scientific and clinical considerations.
Why product profiles matter for development planning
The World Health Organization describes product profiles as planning tools that specify intended use, target populations and desired attributes. They can support evidence generation for regulatory submissions and align research priorities between developers and funders. WHO distinguishes target product profiles, which include minimum essential and optimal characteristics, from preferred product characteristics, which offer strategic preferences without minimum acceptable criteria.
That framework helps explain the relevance to translational research: a proposed profile makes development expectations available for scrutiny while the agency is inviting changes. For university teams assessing how laboratory work could move toward a usable product, the CDC questions bring scientific value and prospects for commercial development into the same discussion.
Independent coverage highlights the consultation’s scope
In November 16 reporting, Edit USA’s David Powell emphasised the distinction between proposed product goals and a product approval, trial announcement or vaccination programme. The report also drew attention to the separate docket for each product, despite the shared deadline.
Regulatory training publisher Learn Laws, in its analysis of the diagnostic consultation, highlighted the operational and economic questions facing developers and laboratories. Its account singled out the potential role of an expedited assay in evaluating prospective preventive and therapeutic interventions, a question CDC expressly includes in the notice.
How research institutions can contribute
CDC invites written views, recommendations and data from scientific research, advocacy and clinical practice communities, as well as the general public. Contributors may address some or all of the questions, suggest other relevant factors and include links to supporting online material or interactive presentations. The notices request concise, plain-language narrative responses.
Submissions must identify CDC and the appropriate docket number. They can be submitted through Regulations.gov or by mail to the Arboviral Diseases Branch in Fort Collins, Colorado, using the address in each notice. CDC does not accept comments by email. Institutions preparing contributions across more than one product area have three distinct records to consider.
The public-record provisions also matter to research and technology-transfer offices. Comments, attachments and supporting material are subject to public disclosure, and identifying information included in a submission can be displayed. CDC advises against including information considered confidential or inappropriate for disclosure. Although the notices discuss marking proprietary material separately and possible agency redaction or withholding, contributors should not treat that as a guarantee of confidentiality.
What happens after January 15
Written comments for all three profiles must be received on or before January 15, 2027. CDC says all comments will be considered in preparing the final profiles. Each notice states that the agency anticipates publication in a peer-reviewed scientific journal within the next six months, followed by availability on the journal’s website. That is an anticipated publication window rather than a fixed release date.
Sources
- CDC / Federal Register: Target Product Profile for a Human West Nile Virus Vaccine: Request for Information, November 16, 2026; checked 2026-11-17.
- CDC / Federal Register: Target Product Profile for Monoclonal Antibodies for West Nile Virus Disease Prevention: Request for Information, November 16, 2026; checked 2026-11-17.
- CDC / Federal Register: Target Product Profile for a Rapid Diagnostic Test for West Nile Virus Disease: Request for Information, November 16, 2026; checked 2026-11-17.
- WHO: Target Product Profiles, preferred product characteristics and target regimen profiles, undated; checked 2026-11-17.
- Edit USA: CDC asks what a human West Nile vaccine and rapid test should do, November 16, 2026; checked 2026-11-17.
- Learn Laws: CDC Solicits Public Input on Target Product Profile for Rapid West Nile Virus Diagnostics, November 16, 2026; checked 2026-11-17.







